Multiple people shot along I-75 south of Lexington, Kentucky, authorities say
Police say active shooter in Kentucky left numerous people shot
Musk says SpaceX to launch first uncrewed Starships to Mars in two years
Pope to bring in a ton of humanitarian aid to remote Papua New Guinea as he celebrates periphery
North Korean leader emphasises importance of strengthening naval power
Former director of Los Alamos National Laboratory dead after car crash in New Mexico
Tennis-Sabalenka survives Pegula storm to win U.S. Open women's title
Anderson .Paak's 'K-Pops' draws on an identity rooted in two cultures
(Reuters) - Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court.
The Justice Department last week had accused Regeneron of manipulating Medicare's drug-pricing process by inflating the average sales price for its Eylea drug.
(Reporting by Kanjyik Ghosh in Bengaluru; Editing by Shilpi Majumdar)
